KZR-616

DRUG4 trials

Sponsors

Kezar Life Sciences, Inc.

Conditions

Autoimmune Hemolytic AnemiaDermatomyositisImmune ThrombocytopeniaLupus NephritisPolymyositisSystemic Lupus Erythematosus

Phase 1

A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

CompletedNCT03393013

Kezar Life Sciences, Inc.Lupus Nephritis, Systemic Lupus Erythematosus

Start: 2018-02-20End: 2022-08-04Updated: 2025-11-18

Phase 2

A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis

CompletedNCT04033926

Kezar Life Sciences, Inc.Dermatomyositis, Polymyositis

Start: 2020-01-14End: 2022-04-06Updated: 2025-11-19

A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP

WithdrawnNCT04039477

Kezar Life Sciences, Inc.Autoimmune Hemolytic Anemia, Immune Thrombocytopenia

Start: 2020-07-31End: 2020-08-05Updated: 2020-08-07

Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.

CompletedNCT04628936

Kezar Life Sciences, Inc.Dermatomyositis, Polymyositis

Start: 2020-11-04End: 2023-06-12Updated: 2025-11-19